Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

08:38 EDT 6 Aug 2018 | Reuters

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

More From BioPortfolio on "Regeneron to invest $100 million in bluebird, jointly develop cancer therapies"